← Leaderboards
Hari S Conjeevaram
University Of Chicago
$3,259,890
Attributed
$4,124,147
Total exposure
12
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $387.5K · FY2005–15$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$4,124,147 · 12
By mechanism
R01$1,728,515 · 1
U01$1,210,294 · 1
M01$885,165 · 9
R03$300,173 · 1
Top collaborators
- Elif Arioglu Oral5 shared
Most similar at University Of Chicago
Same institution · by research overlap
- Angus M Macnicol$6,666,427
- Sonia Kupfer$5,816,081
- Lynda M Brady$0
- Xiaochuan Pan$13,376,969
- Emil Y Sidky$4,012,598
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectHepatitis CFatty LiverInflammationImmunotherapyClinical ResearchRibavirinFibrosisHuman Therapy EvaluationCombination ChemotherapyInsulin ResistanceInterferon AlphaLiver Disorder ChemotherapyLiverChronic Disease /DisorderPlacebosDouble-Blind MethodNonalcoholic SteatohepatitisBiopsyObesityLiver DiseasesFundingCirrhosisFatty Acid Glycerol Esters
Grant awards (25)
Effects of recombinant human leptin in nonalcoholic fatty liver disease (NAFLD)$338,213
R01 · FY2015 · DK
Effects of recombinant human leptin in nonalcoholic fatty liver disease (NAFLD)$338,213
R01 · FY2014 · DK
Effects of recombinant human leptin in nonalcoholic fatty liver disease (NAFLD)$326,376
R01 · FY2013 · DK
Effects of recombinant human leptin in nonalcoholic fatty liver disease (NAFLD)$338,213
R01 · FY2012 · DK
Effects of recombinant human leptin in nonalcoholic fatty liver disease (NAFLD)$387,500
R01 · FY2011 · DK
Fenofibrate for the treatment of patients with NASH$147,592
R03 · FY2007 · DK · contact PI
PIOGLITAZONE IN HEP C: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY$63,946
M01 · FY2007 · RR · contact PI
FENOFIBRATE FOR TREATMENT OF NASH: A RANDOM, DOUBLE BLIND, PLACEBO-CTRLD STUDY$32,085
M01 · FY2007 · RR · contact PI
Fenofibrate for the treatment of patients with NASH$152,581
R03 · FY2006 · DK · contact PI
FENOFIBRATE FOR TREATMENT OF NASH: A RANDOM, DOUBLE BLIND, PLACEBO-CTRLD STUDY$57,740
M01 · FY2006 · RR · contact PI
PIOGLITAZONE IN HEPATITIS C: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUD$44,965
M01 · FY2006 · RR · contact PI
VIRAHEP-C$19,928
M01 · FY2006 · RR · contact PI
VIRAHEP-C$148,731
M01 · FY2005 · RR
PREDICTORS OF HISTOLOGIC SEVERITY IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)$25,733
M01 · FY2005 · RR
FENOFIBRATE FOR TREATMENT OF NASH: A RANDOM, DOUBLE BLIND, PLACEBO-CTRLD STUDY$514
M01 · FY2005 · RR
VIRAHEP-C: A multi-center, collaborative clinical trial$420,870
M01 · FY2004 · RR
VIRAHEP-C Clinical Center$241,165
U01 · FY2004 · DK
Predictors of Histologic Severity in Non-Alcoholic Fatty Liver Disease (NAFLD)$38,630
M01 · FY2004 · RR
Dietary Intervention on Histologic Improvement in Non-Alcoholic Steatohepatitis$32,023
M01 · FY2004 · RR
VIRAHEP-C Clinical Center$375,000
U01 · FY2003 · DK
VIRAHEP-C Clinical Center$365,000
U01 · FY2002 · DK
COMBINED RIBAVIRIN AND INTRON-A IN PEDIATRIC PATIENTS WITH CHRONIC HEPATITIS C$0
M01 · FY2002 · RR
VIRAHEP-C Clinical Center$229,129
U01 · FY2001 · DK
COMBINED RIBAVIRIN AND INTRON-A IN PEDIATRIC PATIENTS WITH CHRONIC HEPATITIS C$0
M01 · FY2000 · RR
COMBINED RIBAVIRIN AND INTRON-A IN PEDIATRIC PATIENTS WITH CHRONIC HEPATITIS C$0
M01 · FY2000 · RR